Clinical Report: A New Marker of Multiple Sclerosis Progression?

Overview

This study identifies lipid-filled immune cells, termed foamy microglia, as potential markers of disease progression in secondary progressive multiple sclerosis (SPMS).

Background

Multiple sclerosis (MS) is a chronic neuro-inflammatory and neurodegenerative disease characterized by relapsing and progressive phases. Understanding the mechanisms behind disease progression, particularly in secondary progressive MS, is crucial.

Data Highlights

The study analyzed postmortem brain tissue from patients with secondary progressive MS, revealing that lesions with foamy microglia were linked to faster disease progression.

Key Findings

• Foamy microglia, lipid-filled immune cells, are associated with faster disease progression in SPMS.
• Patients with more foamy lesions reached disability milestones sooner than those with fewer.
• Remyelinated lesions were linked to slower disease progression.
• Foamy microglia exhibited abnormal lipid metabolism and impaired waste processing.
• Monoacylglycerol lipase (MAGL) was identified as a potential therapeutic target.
• Lipid molecules known as oxylipins may serve as biomarkers for chronic lesion activity.

Clinical Implications

The identification of foamy microglia and related lipid markers may provide new avenues for monitoring disease progression in MS.

Conclusion

This research suggests that foamy microglia may serve as a marker for chronic active lesions.

Related Resources & Content

1. Frontiers in Neurology, 2026 -- From inflammation to neurodegeneration: an exploratory pilot study of a diagnostic framework for progression in MS
2. Acta Neuropathologica, 2025 -- Examining the Unaffected White and Gray Matter in Multiple Sclerosis: Connections to Chronic Progression
3. Brain, 2025 -- Distinct transcriptional changes distinguish efficient and poor remyelination in multiple sclerosis
4. Frontiers in Neurology, 2026 -- Multiple sclerosis as a biological and clinical continuum: from risk factors to the early stages of disease
5. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria - PubMed
6. Brain, 2025 -- Chronic active lesions on MRI
7. New England Journal of Medicine -- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
8. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria - PubMed
9. https://academic.oup.com/brain/article/147/9/2913/7558434
10. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis | New England Journal of Medicine